行情

ACAD

ACAD

阿卡迪亚
NASDAQ

实时行情|Nasdaq Last Sale

45.24
+2.63
+6.17%
盘后: 45.50 +0.26 +0.57% 18:43 11/11 EST
开盘
42.75
昨收
42.61
最高
45.87
最低
42.39
成交量
260.54万
成交额
--
52周最高
45.87
52周最低
14.01
市值
69.46亿
市盈率(TTM)
-25.7309
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ACAD 新闻

  • IBD Stock Of The Day Breaks Out As It Stares Down A Massive Opportunity
  • Investor's Business Daily.5小时前
  • ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimers Disease (CTAD) Meeting on December 4, 2019
  • Business Wire.9小时前
  • JP Morgan Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $35
  • Benzinga.4天前
  • Have Insiders Been Selling ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares?
  • Simply Wall St..4天前

更多

所属板块

生物技术和医学研究
-0.51%
制药与医学研究
-0.43%

热门股票

名称
价格
涨跌幅

ACAD 简况

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.
展开

Webull提供ACADIA Pharmaceuticals Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。